Action Pharma secures funds for critical Phase II trial as it seeks development partner
This article was originally published in Scrip
Executive Summary
Action Pharma of Denmark has secured a convertible loan of €5 million from its four investors, in addition to the €2 million loan secured at the start of the year, which will be used to finance ongoing clinical studies of its lead drug candidate AP214. AP214 is a modified DMSH-peptide analogue in Phase IIa studies for the protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as its lead indication.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.